Fundamental Analysis of Eagle Pharmaceuticals Inc - Growth / Value Index
EGRX - Valuation Highlights
Valuation Analysis
Tsr Value Index - Good Score of 68.75
Undervalued - Price to Intrinsic Value of 0.0214
Price to Earning Ratio is 2.64 and EV to EBITDA is 1.57 suggesting company is undervalued.
Price to Book Ratio is 0.171 indicating that it is undervalued.
Book Value in last 3 years is trending up
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 2.69 | 1.74 | 101.31 % | |
| Price to Book | 0.174 | 0.266 | -24.52 % | 0.066 |
| Price to Sales | 0.163 | 0.196 | -45.87 % | |
| Enterprise Value to EBITDA Multiple | 1.59 | 1.06 | -73.83 % |
EGRX - Profitability Highlights
Profitability Analysis
Earning Yield of 37.84 %
Net profit has jumped from negative to positive
Company Earning excess return
EBITDA is continuously increasing for last 3 Years
Good Return On Capital Employed of 12.04
Very Low Dividend Yield of 0 %
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 6.48 | 15.26 | 5841.43 % | 2.05 |
| Return On Asset | 3.90 | 8.78 | 4847.53 % | 1.28 |
| Net Profit Margin | 6.04 | 11.26 | 4217.61 % | 7.99 |
| Operating Profit Margin | 15.92 | 25.57 | 1484.18 % | 15.94 |
| EBITDA Margin | 16.76 | 20.68 | 1564.19 % | 16.62 |
Highlights
| Market Cap | 61681.03 K |
| Enterprise Value | 68826.03 K |
| Price/Book TTM | 0.174 |
| Outstanding Share | 12958.20 K |
| Float/ Outstanding Share | 69.49% |
| Dividend Yield | 0 % |
Share Holding
Guru Numbers
| Price/Graham No | 0.179 |
| Peter Lynch Ratio | 0 |
| Piotroski F Score | 6.00 |
| Altman Z Score | 2.04 |
| Sloan Ratio | 0.177 |
| Peter Lynch Fair Value | 0 |
EGRX - Growth Highlights
Growth Analysis
STRONG JUMP IN NET SALE : YoY growth
Steady increase in Total Assets for last 3 Years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 257551 K | 84.56 % | 2.50 % |
| Gross Profit | 179876 K | 71.35 % | 2.48 % |
| EBITDA | 43175.00 K | 2802.35 % | 8.52 % |
| Net Profit | 15566.00 K | 7699.57 % | 10.19 % |
| EPS | 1.77 | 7706.44 % | NA |
EGRX - Stability Highlights
Stability Analysis
Tsr Stability Index - Good Score of 73.44
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.267 | 84.30 % | 0.278 |
| Cash Ratio | 0.498 | -62.07 % | |
| Quick Ratio | 1.27 | -37.37 % | 1.67 |
| Shareholders Equity | 57.50 | -17.31 % | |
| Debt to EBITDA | 0.954 | 109.03 % |
Historical Valuation Ratios of Eagle Pharmaceuticals Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Eagle Pharmaceuticals Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Eagle Pharmaceuticals Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Eagle Pharmaceuticals Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)